European Industry Played Key Role In Mitigating COVID-19
Detailed Modelling And Industry Co-ordination Were Central To Managing Pandemic
Executive Summary
In the first part of an exclusive two-part interview, James Burt – Accord’s executive vice-president for Europe, the Middle East and North Africa – talks to Generics Bulletin about the key actions taken by the generics industry to mitigate the coronavirus pandemic, and the changed landscape that the off-patent arena can expect to see in future.
You may also be interested in...
Challenges Remain For Off-Patent Industry’s COVID Response
At an symposium convened by the WHO, WIPO and WTO, the IGBA has highlighted ongoing challenges for the off-patent industry’s continuing response to the COVID-19 pandemic.
Musical Chairs For Off-Patent Executives In 2021
Last year was a year of significant executive changes in the off-patent industry, with numerous high-profile hires and departures from companies like Sandoz, Teva, Viatris, Hikma, Fresenius, Neuraxpharm and Stada.
Central Role For Industry Beckons As Europe Rebuilds After COVID
Generic and biosimilar medicines must become central to European healthcare policy as the region looks to rebuild in the wake of the COVID-19 pandemic, Medicines for Europe’s new president, Rebecca Guntern of Sandoz, tells Generics Bulletin in an exclusive interview.